Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1992 Jan;33(1):93–99. doi: 10.1111/j.1365-2125.1992.tb04006.x

The pharmacokinetics of perindopril and its effects on serum angiotensin converting enzyme activity in hypertensive patients with chronic renal failure.

J Sennesael 1, A Ali 1, P Sweny 1, M Vandenburg 1, D Slovic 1, M Dratwa 1, G Resplandy 1, P Genissel 1, P Desche 1
PMCID: PMC1381205  PMID: 1311597

Abstract

1. Perindopril, an orally active angiotensin converting enzyme inhibitor, was given to 23 hypertensive patients with stable chronic renal failure for 15 days. The dose of perindopril was 2 or 4 mg once a day according to the degree of renal failure. The creatinine clearance of the patients ranged from 6 to 67 ml min-1 1.73 m-2. The pharmacokinetics of perindopril and perindoprilat, its active metabolite, were studied after acute and chronic administration of perindopril. 2. The drug was well tolerated and creatinine clearance was unaltered by treatment. 3. In both groups, steady-state was reached within 3 days of chronic treatment. 4. After both acute and chronic drug administration renal impairment had no effect on perindopril pharmacokinetics but the pharmacokinetics of perindoprilat were altered significantly. After chronic administration the serum accumulation ratio was 1.81 in patients with mild renal failure and 5.35 in patients with severe renal failure. Chronic administration did not modify the renal clearance of perindoprilat nor its elimination half-life. 5. A significant correlation between the renal clearance of perindoprilat and creatinine clearance was observed (r = 0.87 first dose, r = 0.83 last chronic dose). 6. A non-linear relationship between serum perindoprilat concentration and inhibition of angiotensin converting enzyme was described by a modified Hill equation. Values of IC50 were 1.11 +/- 0.07 micrograms I-1 (mean +/- s.d.) in patients with severe renal failure and 1.81 +/- 0.20 micrograms l-1 in patients with moderate renal failure. Chronic administration increased maximal inhibition and decreased the time to maximal inhibition only in patients with severe renal failure.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
93

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aurell M., Delin K., Herlitz H., Ljungman S., Witte P. U., Irmisch R. Pharmacokinetics and pharmacodynamics of ramipril in renal failure. Am J Cardiol. 1987 Apr 24;59(10):65D–69D. doi: 10.1016/0002-9149(87)90056-7. [DOI] [PubMed] [Google Scholar]
  2. Debusmann E. R., Pujadas J. O., Lahn W., Irmisch R., Jané F., Kuan T. S., Mora J., Walter U., Eckert H. G., Hajdú P. Influence of renal function on the pharmacokinetics of ramipril (HOE 498). Am J Cardiol. 1987 Apr 24;59(10):70D–78D. doi: 10.1016/0002-9149(87)90057-9. [DOI] [PubMed] [Google Scholar]
  3. Devissaguet J. P., Ammoury N., Devissaguet M., Perret L. Pharmacokinetics of perindopril and its metabolites in healthy volunteers. Fundam Clin Pharmacol. 1990;4(2):175–189. doi: 10.1111/j.1472-8206.1990.tb00486.x. [DOI] [PubMed] [Google Scholar]
  4. Doucet L., De Veyrac B., Delaage M., Cailla H., Bernheim C., Devissaguet M. Radioimmunoassay of a new angiotensin-converting enzyme inhibitor (perindopril) in human plasma and urine: advantages of coupling anion-exchange column chromatography with radioimmunoassay. J Pharm Sci. 1990 Aug;79(8):741–745. doi: 10.1002/jps.2600790817. [DOI] [PubMed] [Google Scholar]
  5. Francis R. J. ELSMOS--an extended least squares modelling system in FORTRAN IV for mini- or micro-computer implementation. Comput Programs Biomed. 1984 Feb-Apr;18(1-2):43–49. doi: 10.1016/0010-468x(84)90022-9. [DOI] [PubMed] [Google Scholar]
  6. Giudicelli J. F., Chaignon M., Richer C., Giroux B., Guedon J. Influence of chronic renal failure on captopril pharmacokinetics and clinical and biological effects in hypertensive patients. Br J Clin Pharmacol. 1984 Nov;18(5):749–758. doi: 10.1111/j.1365-2125.1984.tb02538.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Jackson B., Cubela R. B., Conway E. L., Johnston C. I. Lisinopril pharmacokinetics in chronic renal failure. Br J Clin Pharmacol. 1988 Jun;25(6):719–724. doi: 10.1111/j.1365-2125.1988.tb05258.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kaiser G., Ackermann R., Sioufi A. Pharmacokinetics of a new angiotensin-converting enzyme inhibitor, benazepril hydrochloride, in special populations. Am Heart J. 1989 Mar;117(3):746–751. doi: 10.1016/0002-8703(89)90765-5. [DOI] [PubMed] [Google Scholar]
  9. Kelly J. G., Doyle G., Donohue J., Laher M., Vandenburg M. J., Currie W. J., Cooper W. D. Pharmacokinetics of enalapril in normal subjects and patients with renal impairment. Br J Clin Pharmacol. 1986 Jan;21(1):63–69. doi: 10.1111/j.1365-2125.1986.tb02823.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lecocq B., Funck-Brentano C., Lecocq V., Ferry A., Gardin M. E., Devissaguet M., Jaillon P. Influence of food on the pharmacokinetics of perindopril and the time course of angiotensin-converting enzyme inhibition in serum. Clin Pharmacol Ther. 1990 Mar;47(3):397–402. doi: 10.1038/clpt.1990.45. [DOI] [PubMed] [Google Scholar]
  11. Lees K. R., Reid J. L. Effects of intravenous S-9780, an angiotensin-converting enzyme inhibitor, in normotensive subjects. J Cardiovasc Pharmacol. 1987 Aug;10(2):129–135. doi: 10.1097/00005344-198708000-00001. [DOI] [PubMed] [Google Scholar]
  12. Lees K. R., Reid J. L. The haemodynamic and humoral effects of treatment for one month with the angiotensin converting enzyme inhibitor perindopril in salt replete hypertensive patients. Eur J Clin Pharmacol. 1987;31(5):519–524. doi: 10.1007/BF00606623. [DOI] [PubMed] [Google Scholar]
  13. Lowenthal D. T., Irvin J. D., Merrill D., Saris S., Ulm E., Goldstein S., Hichens M., Klein L., Till A., Harris K. The effect of renal function on enalapril kinetics. Clin Pharmacol Ther. 1985 Dec;38(6):661–666. doi: 10.1038/clpt.1985.242. [DOI] [PubMed] [Google Scholar]
  14. Macfadyen R. J., Lees K. R., Reid J. L. Perindopril. A review of its pharmacokinetics and clinical pharmacology. Drugs. 1990;39 (Suppl 1):49–63. doi: 10.2165/00003495-199000391-00009. [DOI] [PubMed] [Google Scholar]
  15. Onoyama K., Nanishi F., Okuda S., Oh Y., Fujishima M., Tateno M., Omae T. Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (delapril) in patients with deteriorated kidney function and in normal control subjects. Clin Pharmacol Ther. 1988 Mar;43(3):242–249. doi: 10.1038/clpt.1988.27. [DOI] [PubMed] [Google Scholar]
  16. Rakhit A., Radensky P., Szerlip H. M., Kochak G. M., Audet P. R., Hurley M. E., Feldman G. M. Effect of renal impairment on disposition of pentopril and its active metabolite. Clin Pharmacol Ther. 1988 Jul;44(1):39–48. doi: 10.1038/clpt.1988.110. [DOI] [PubMed] [Google Scholar]
  17. Salvetti A. Newer ACE inhibitors. A look at the future. Drugs. 1990 Dec;40(6):800–828. doi: 10.2165/00003495-199040060-00004. [DOI] [PubMed] [Google Scholar]
  18. Shionoiri H., Gotoh E., Takagi N., Takeda K., Yabana M., Kaneko Y. Antihypertensive effects and pharmacokinetics of single and consecutive doses of cilazapril in hypertensive patients with normal and impaired renal function. J Cardiovasc Pharmacol. 1988 Feb;11(2):242–249. [PubMed] [Google Scholar]
  19. Verpooten G. A., Genissel P. M., Thomas J. R., De Broe M. E. Single dose pharmacokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insufficiency. Br J Clin Pharmacol. 1991 Aug;32(2):187–192. doi: 10.1111/j.1365-2125.1991.tb03880.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Zanchetti A., Desche P. Perindopril: first-line treatment for hypertension. Clin Exp Hypertens A. 1989;11 (Suppl 2):555–573. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES